Published in Genes Chromosomes Cancer on October 01, 1998
European Low and Intermediate Risk Neuroblastoma Protocol | NCT01728155
Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci U S A (2001) 2.16
Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res (2010) 1.81
Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. Neoplasia (2003) 1.64
Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One (2009) 1.55
Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br J Cancer (2007) 1.39
Mutational dynamics between primary and relapse neuroblastomas. Nat Genet (2015) 1.36
MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des (2009) 1.18
Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol (2001) 1.03
The connections between neural crest development and neuroblastoma. Curr Top Dev Biol (2011) 1.01
Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis. Br J Cancer (2001) 1.00
Neuroblastoma. Semin Pediatr Surg (2012) 0.97
Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn (2000) 0.97
CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. BMC Cancer (2008) 0.95
Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform. Genome Res (2005) 0.95
The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Med (2009) 0.89
Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11. BMC Genomics (2005) 0.87
High-level amplification at 17q23 leads to coordinated overexpression of multiple adjacent genes in breast cancer. Br J Cancer (2007) 0.87
No evidence for involvement of SDHD in neuroblastoma pathogenesis. BMC Cancer (2004) 0.85
Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24. Br J Cancer (1999) 0.84
The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma. Int J Cancer (2016) 0.81
Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status. Br J Cancer (2000) 0.79
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA (1992) 7.84
Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet (1998) 7.68
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature (1998) 7.55
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med (1998) 4.95
Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem (1983) 3.91
Further delineation of the 15q13 microdeletion and duplication syndromes: a clinical spectrum varying from non-pathogenic to a severe outcome. J Med Genet (2009) 3.87
Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat (2000) 3.87
Detection and characterisation of an overmodified type III collagen by analysis of non-cutaneous connective tissues in a patient with Ehlers-Danlos syndrome IV. J Med Genet (1992) 3.80
Emerging patterns of cryptic chromosomal imbalance in patients with idiopathic mental retardation and multiple congenital anomalies: a new series of 140 patients and review of published reports. J Med Genet (2006) 3.70
Cyclic AMP levels in fibroblasts: relationship to growth rate and contact inhibition of growth. Biochem Biophys Res Commun (1971) 3.58
Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med (1999) 3.03
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet (2004) 2.96
Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet (2007) 2.91
Regulation of cell growth by cyclic adenosine 3',5'-monophosphate. Effect of cell density and agents which alter cell growth on cyclic adenosine 3',5'-monophosphate levels in fibroblasts. J Biol Chem (1972) 2.85
EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet (1993) 2.72
Modification of DAPI banding on human chromosomes by prestaining with a DNA-binding oligopeptide antibiotic, distamycin A. Exp Cell Res (1978) 2.71
Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med (1996) 2.66
The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia (2006) 2.57
Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci Transl Med (2010) 2.55
The molecular genetics of Marfan syndrome and related disorders. J Med Genet (2006) 2.45
Type III allergic reaction after infusion of immunoglobulins. Lancet (1990) 2.45
How fast is fast enough for clinical laboratory turnaround time? Measurement of the interval between result entry and inquiries for reports. Am J Clin Pathol (1997) 2.36
Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Arch Intern Med (2001) 2.34
D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene (1991) 2.21
PHF6 mutations in adult acute myeloid leukemia. Leukemia (2010) 2.20
Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol (1999) 2.20
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer (2009) 2.13
Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood (2001) 2.12
Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood (1996) 2.01
Quality assessment of genetic markers used for therapy stratification. J Clin Oncol (2003) 1.92
MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene (2009) 1.90
Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. Am J Hum Genet (1996) 1.89
Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.88
Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype--phenotype correlation. Hum Mol Genet (2001) 1.84
A spectrum of ABCC6 mutations is responsible for pseudoxanthoma elasticum. Am J Hum Genet (2001) 1.73
Absolute pulse energy measurements of soft x-rays at the Linac Coherent Light Source. Opt Express (2014) 1.73
Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.72
Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood (1995) 1.71
Localized avascular necrosis of lesser curve of stomach complicating highly selective vagotomy. Br Med J (1975) 1.63
Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood (1998) 1.63
EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia (2012) 1.60
Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2. Eur J Cancer (2004) 1.60
Delineation of two distinct 6p deletion syndromes. Hum Genet (1999) 1.59
The continent ileostomy of Kock (ileal intra-abdominal reservoir). Experience with 9 cases operated on for ulcerative colitis. Br J Surg (1975) 1.58
Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Hum Mutat (2004) 1.57
A mutation in a rous sarcoma virus gene that controls adenosine 3',5'-monophosphate levels and transformation. J Biol Chem (1972) 1.56
Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell Melanoma Res (2010) 1.54
Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev (2001) 1.54
Control of nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis among healthcare workers and HIV-infected patients. Lancet (1995) 1.52
Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene (2001) 1.51
Exon 10b of the NF1 gene represents a mutational hotspot and harbors a recurrent missense mutation Y489C associated with aberrant splicing. Genet Med (2001) 1.50
High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol (1991) 1.49
Light-directed synthesis of high-density oligonucleotide arrays using semiconductor photoresists. Proc Natl Acad Sci U S A (1996) 1.48
Tumour infiltration depth ≥4 mm is an indication for an elective neck dissection in pT1cN0 oral squamous cell carcinoma. Oral Oncol (2011) 1.48
Pretreatment prognostic factors for children with hepatoblastoma-- results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer (2000) 1.47
The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant (2008) 1.46
Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Hum Mol Genet (1995) 1.45
Recessive osteogenesis imperfecta caused by LEPRE1 mutations: clinical documentation and identification of the splice form responsible for prolyl 3-hydroxylation. J Med Genet (2008) 1.45
Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol (2000) 1.44
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer (1999) 1.44
An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene (2010) 1.43
Cytogenetic and array-CGH characterization of a 6q27 deletion in a patient with developmental delay and features of Ehlers-Danlos syndrome. Am J Med Genet A (2010) 1.43
Alkane utilization in Pseudomonas oleovorans. Structure and function of the regulatory locus alkR. J Biol Chem (1988) 1.43
Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapy. Med Pediatr Oncol (1995) 1.41
Contribution of molecular analyses in diagnosing Marfan syndrome and type I fibrillinopathies: an international study of 1009 probands. J Med Genet (2008) 1.41
Type III collagen mutations in Ehlers Danlos syndrome type IV and other related disorders. Clin Exp Dermatol (1988) 1.38
The soft x-ray instrument for materials studies at the linac coherent light source x-ray free-electron laser. Rev Sci Instrum (2012) 1.36
Characteristic pattern of chromosomal gains and losses in Merkel cell carcinoma detected by comparative genomic hybridization. Cancer Res (1998) 1.35
Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia (2012) 1.35
Dominantly inherited cleft lip and palate. J Med Genet (1989) 1.35
Ethics and pharmaceutical medicine -- the full report of the Ethical Issues Committee of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK. Int J Clin Pract (2006) 1.34
Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood (1995) 1.34
Diverse mutations in the gene for cartilage oligomeric matrix protein in the pseudoachondroplasia-multiple epiphyseal dysplasia disease spectrum. Am J Hum Genet (1998) 1.33
1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer (1994) 1.31
The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer (1997) 1.30
A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer (2012) 1.28
CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood (1998) 1.28
Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. Leukemia (2008) 1.27
Coherence properties of individual femtosecond pulses of an x-ray free-electron laser. Phys Rev Lett (2011) 1.26
Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene (1997) 1.26
Guiding Principles for Pharmaceutical Physicians from the Ethical Issues Committee of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK. Int J Clin Pract (2006) 1.25
Classification of pseudoxanthoma elasticum: report of a consensus conference. J Am Acad Dermatol (1994) 1.25